Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Earnings for Petros Pharmaceuticals, Inc. (PTPI)
Earnings in 2023 (TTM): $-8,163,188
According to Petros Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-8,163,188. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Petros Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-8,163,188 | $-8,163,188 |
| 2022 | $-20,037,573 | $-27,037,573 |
| 2021 | $-8,986,676 | $-9,355,336 |
| 2020 | $-22,012,918 | $-20,585,925 |
| 2019 | $-33,157,166 | $-32,511,300 |
| 2018 | $-32,486,072 | $-32,472,707 |